Case commentary reveals cefiderocol plus sulbactam-durlobactam's effectiveness in recurrent Burkholderia cenocepacia infections, highlighting treatment complexities.
In this issue, B. Gaglani, T. M. Andermann, C. Wate, J. Oldan, et al. (Antimicrob Agents Chemother 70:e01542-25, 2026, https://doi.org/10.1128/aac.01542-25 ) describe a recurrent Burkholderia cenocepacia infection successfully treated with cefiderocol plus sulbactam-durlobactam. Treatment decisions are often made with incomplete microbiological and pharmacological data, even as interest in mechanism-based β-lactam combination strategies continues to grow. This case supports the utility of cefiderocol plus sulbactam-durlobactam in B. cenocepacia infection and reinforces the importance of multidisciplinary approaches to better estimate the risk of treatment failure and optimize antimicrobial therapy.
No takes yet. Share an insight, caveat, or question.
Giuliano et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: